Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
MK0974 Ethanolate formulation · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| 1 | ACTIVE_COMPARATOR | MK0974 Ethanolate |
| 2 | ACTIVE_COMPARATOR | MK0974 Hydrate |
| Name | Type | Description |
|---|---|---|
| MK0974 Ethanolate formulation | DRUG | Single dose MK0974 280 mg tablet in one of two treatment periods |
| Comparator: MK0974 Hydrate formulation | DRUG | Single dose MK0974 280 mg tablet in one of two treatment periods |
Inclusion Criteria: * Subject is in good health * Subject is a non-smoker * Subject is willing to comply with the study restrictions Exclusion Criteria: * Subject has a history of stroke, chronic seizures, or major neurological disorder * Subject has a history of cancer * Subject is a nursing mot...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| AbbVie, Inc. | ABBV | 13 | PHASE3 | Atogepant |
| Pfizer Inc. | PFE | 9 | PHASE3 | Rimegepant |
| Eli Lilly and Company | LLY | 2 | PHASE3 | Galcanezumab |
| Amgen Inc. | AMGN | 2 | PHASE3 | Erenumab Dose 1 |
| Ki Health Partners. LLC | RVNC | 1 | - | Daxibotulinumtonix A |
MK0974 Ethanolate formulation is an investigational small molecule being developed for the treatment of migraine. It is currently in Phase 1 clinical development and is not yet approved by regulatory authorities.
MK0974 Ethanolate formulation is being developed by Merck & Company, Inc. (NYSE: MRK). The company is conducting clinical trials to evaluate this investigational migraine treatment.
MK0974 Ethanolate formulation is in Phase 1 clinical development. It is an investigational drug and has not been approved for any use. One Phase 1 trial has been completed.
MK0974 Ethanolate formulation has one completed clinical trial, NCT00965887, titled "Bioequivalence of Two Tablet Forms of MK0974 (0974-045)." This Phase 1 study enrolled 36 participants and evaluated the drug in healthy volunteers.
MK0974 Ethanolate formulation is a specific formulation of MK0974, the active drug substance. The clinical trial NCT00965887 compares two tablet forms of MK0974, including the ethanolate formulation, to assess their bioequivalence.